Introduction
Zonisamide is an anticonvulsant drug well tolerated as monotherapy in patients with partial onset epilepsy, and also effective for the treatment of generalized epilepsy. The mechanism by which zonisamide acts is thought to be the blocking of voltagesensitive sodium and T-type calcium channels, resulting in stabilization of neuronal membranes and suppression of neuronal hypersynchronization. It is remarkable for its long half-life (63-69 h), allowing for once-a-day dosing. Zonisamide is rapidly and completely absorbed, with peak absorption occurring at 2-6 h, and metabolism occurring primarily through cytochrome P450 isozyme 3A4 (CYP3A4), followed by renal excretion [1, 2] . It takes 10-12 days to reach steady state serum levels. Typically dosed at 100-600 mg daily with a recommended therapeutic range of 10-40 mcg/mL [3] , it is routinely initiated as 100 mg daily with uptitration 100 mg every week. Depending on the effective dose, with this titration schedule, it may take 4-6 weeks to reach a steady state therapeutic serum level. We administered a large initial dose of zonisamide, which we termed a ''loading dose'', to 32 patients within our epilepsy monitoring unit, with the goal of achieving a therapeutic serum level more quickly than the recommended titration schedule allows, to facilitate discharge and decrease hospital length of stay. We found that this was both a safe and well-tolerated method of initiating zonisamide therapy.
Methods
Our retrospective study included 32 adult (age >18) inpatients of the epilepsy monitoring unit of Columbia University Medical Center from 2011 to 2015, who were initiated on zonisamide therapy during their hospitalization using a ''loading dose'' which was defined as three times the target maintenance dose, given in two divided doses, 6 h apart. In most cases, the reason for using a large initial dose was the desire to achieve a therapeutic serum zonisamide level before discharging the patient. In one case, treatment of refractory focal seizures was the reason for rapid initiation of zonisamide. The large initial dose was given on the first day of therapy, and the initial maintenance dose (usually 200 mg or 300 mg daily) was begun the next day. Serum levels were drawn after administration of the complete dose. Information from follow-up visits, including zonisamide side effects and serum levels were also noted when available. Adverse effects to zonisamide during the hospital stay or immediately upon discharge were gathered from the physician notes, nursing notes, Purpose: There are a limited number of anticonvulsant medications that can be administered with an oral loading dose in order to rapidly achieve an effective serum level, and most of these have associated adverse effects. Zonisamide is approved for the treatment of partial onset epilepsy, and is used in practice for both generalized and partial onset epilepsy. It is generally well-tolerated, has a long half-life, and can be administered once daily. Unfortunately, the recommended titration schedule for initiating therapy takes several weeks to reach target dose and therapeutic serum levels. Methods: We initiated zonisamide therapy using a large initial dose of zonisamide in 32 patients in our epilepsy monitoring unit over the past four years. Results: Adverse effects were rare and involved nausea/vomiting (9.4%) or drowsiness (6.3%). In patients where serum levels were available for review, therapeutic or near-therapeutic levels were achieved after an oral load of 600-900 mg given as divided doses over a 6-12 h period. Conclusion: This report is the first to suggest a method of rapidly initiating zonisamide therapy, achieving therapeutic serum levels in a shorter time frame, with an adverse effect profile similar to the recommended titration schedule.
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or discharge summaries. This research was approved by the Institutional Review Body of Columbia University Medical Center and informed consent was waived for this study.
Results
32 adults were included in this analysis, outlined in Table 1 . Zonisamide was used as monotherapy in 14 patients, dual therapy in 12, and polytherapy in six. Other anticonvulsant drugs included levetiracetam (9), lacosamide (4), phenytoin (3), carbamazepine (2), oxcarbazepine (2), pregabalin (2), valproate (2), and gabapentin (1). The total initial dose was 400-900 mg, divided in 2-3 doses over 4.5-15 h. Most of the patients (26) received 600 mg (two divided doses) as the initial dose. Two patients received a total initial dose of 900 mg (3 divided doses) and four patients received 400 mg (as a single or divided dose). Most divided doses were given 5-7 h apart, in order to improve tolerability.
Five of the 32 patients reported side effects (Fig. 1) . Two patients complained of tiredness (6.3%), one of whom had also been given benzodiazepines. Three patients (9.4%) had nausea or vomited: 1 patient had intractable nausea and vomiting for 5 days until the zonisamide was discontinued, a second patient vomited once within 12 h of the first dose and had no further side effects, and a third patient complained of only nausea, which resolved within several hours after the first dose. The average post-load serum level in patients with nausea/vomiting was 11 mcg/mL. Side effects were not more common in patients who were on multiple anticonvulsant medications. 25 patients were seen in follow-up. The median length of time to follow-up was 11 months. Of these, 12 patients (48%) complained of side effects, and 7 (28%) discontinued zonisamide because of side effects (Fig. 1) . The median length of time to discontinue zonisamide was 7 months (range, 3 days-23 months).
Serum levels were drawn in 12 of the 32 patients ( Table 2) . The median zonisamide level was therapeutic at 10 mcg/mL, including four patients who were also on enzyme-inducing anticonvulsants. The earliest therapeutic level was seen 2 h after the large initial dose and was 15 mcg/mL. There was no significant trend between total initial dose and serum level, but 100% of patients who received a total of 900 mg had a therapeutic level, whereas only 40% of patients who received a total 600 mg had a therapeutic level. The median zonisamide level at follow-up was 14.5 mcg/mL.
Discussion
An oral ''loading dose'' of zonisamide in these patients was generally well-tolerated. Nausea/vomiting and tiredness were the only reported adverse effects and occurred in 15% of our patients. It is notable that after a large initial dose of zonisamide, gastrointestinal (GI) adverse effects were more common than central nervous system (CNS) side effects, although CNS side effects were more common at follow-up, as they were in clinical trials. It is possible that GI side effects could have been mitigated by administration of a All values are listed as median (range) unless otherwise specified. Fig. 1 . Nausea was the most common side effect reported after administration of a ''loading'' dose of zonisamide (blue bars, n = 32). At follow-up, cognitive side effects included mood instability, aggressiveness, and depression (red bars, n = 25). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) the medication with food. It has been suggested based on US safety trials [4, 9] that adverse events are higher in most categories when titration of zonisamide is more rapid; however, we did not note a significantly higher rate of adverse events despite a cumulative dose of up to 900 mg in <24 h. Other published reports of highdose zonisamide ingestion include three cases of overdose, two of which resulted in hypotension, respiratory depression or cardiac arrest and coma in combination with other medications [5, 6] . The third case was an ingestion of 8.7 g of zonisamide, with a plasma level of 110 mg/L at 5.5 h after ingestion, in which the patient suffered from only nausea, chest pain, blurred vision, dizziness and headache, without any metabolic derangements or cardiopulmonary side effects [7] . This suggests that serious adverse events are unlikely to occur from a much lower dose. Side effects may be underestimated in this report, as all were self-reported and not elicited by questionnaire, and depended on the reliable reporting of any noted side effects in the chart. Also there is probably a selection bias, as patients chosen for a large initial dose were likely to be young, otherwise healthy, without renal or hepatic impairment, and less likely to be on anticonvulsant drug polytherapy. The adverse effect rate of long-term follow-up (48% adverse effects, with 28% discontinuing zonisamide) compares with other studies showing rates of 51-61% treatment related adverse effects and 19% resulting in drug discontinuation [8, 9] . The most common adverse effects reported in previous zonisamide trials include ataxia, dizziness, somnolence, tiredness, nausea, headache, agitation, and anorexia [8] , which agrees with our long-term follow-up results. Phenytoin, carbamazepine, and valproate are other anticonvulsant medications that are orally loaded. Oral phenytoin at 20 mg/kg oral loading dose takes 4-8 h to reach therapeutic levels, with up to 50% of patients experiencing dizziness, nausea/vomiting, drowsiness, and nystagmus [10, 11] . Oral loading of carbamazepine result in therapeutic levels 4-18 h after administration with adverse effects in 30-60% of patients of dizziness, nausea, drowsiness, and nystagmus [12] . Oral loading of valproate up to 20 mg/kg resulted in GI upset, dizziness or sedation in up to 50% of patients [13] . In this small series, the adverse effect rate of 16% suggests that zonisamide may actually be better tolerated.
No conclusions regarding optimal loading dose or pharmacokinetics of zonisamide loading can be drawn from this limited study, because timed blood levels were not collected for all the patients. Serum levels were drawn in 12 patients, and indicate that a detectable serum zonisamide level is obtained after an initial dose of 600-900 mg. It is noteworthy that the patients who received 900 mg were more likely to have a therapeutic level than those who had received 600 mg zonisamide. Based on this experience we would recommend a dose of 900 mg. We were concerned primarily about safety and tolerability in this small group of patients, therefore we did not formally calculate a loading dose based on volume of distribution (0.9-1.4 L) and target concentration (10-15 mcg/mL), but had we done so, the result would have been 600-1500 mg.
Conclusion
This is the first report of its kind to suggest a safe and welltolerated method for the rapid initiation of zonisamide therapy using an oral ''loading dose''. This may be useful in patients who need rapid control of seizures or are anticipating imminent hospital discharge on zonisamide monotherapy.
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